Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for COVID-19 with acute respiratory failure (Imam Reza Hospital, Tabriz)
IRCT20200406046968N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of tocilizumab in coronavirus disease 2019 (COVID-19) and acute respiratory decompensation, sponsored by Tabriz University of Medical Sciences. Started Apr 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory decompensation
Beyond the preview
Go deeper on IRCT20200406046968N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200406046968N1.